Alkermes plc (NASDAQ:ALKS) Expected to Post Q1 2025 Earnings of $0.43 Per Share

Alkermes plc (NASDAQ:ALKS) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Alkermes in a research note issued on Thursday, May 2nd. HC Wainwright analyst D. Tsao expects that the company will post earnings of $0.43 per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $35.00 target price on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.39 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.54 EPS and Q4 2025 earnings at $0.52 EPS.

A number of other equities research analysts also recently commented on ALKS. Jefferies Financial Group lifted their target price on Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Piper Sandler reaffirmed an “overweight” rating and set a $39.00 target price on shares of Alkermes in a report on Monday, April 1st. Robert W. Baird initiated coverage on Alkermes in a report on Tuesday, March 19th. They set an “outperform” rating and a $37.00 target price for the company. UBS Group downgraded Alkermes from a “neutral” rating to a “sell” rating and set a $25.00 target price for the company. in a report on Tuesday, February 20th. Finally, TheStreet raised Alkermes from a “c+” rating to a “b” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $35.38.

Alkermes Trading Up 0.8 %

Alkermes stock opened at $24.05 on Monday. The company has a quick ratio of 2.50, a current ratio of 3.20 and a debt-to-equity ratio of 0.23. Alkermes has a 52 week low of $22.01 and a 52 week high of $33.71. The company has a market capitalization of $4.07 billion, a price-to-earnings ratio of 9.51, a price-to-earnings-growth ratio of 0.69 and a beta of 0.61. The stock has a 50-day moving average price of $26.73 and a 200 day moving average price of $26.73.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15). Alkermes had a return on equity of 20.31% and a net margin of 25.17%. The business had revenue of $350.37 million for the quarter, compared to analysts’ expectations of $360.26 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. Alkermes’s revenue was up 21.8% on a year-over-year basis.

Alkermes announced that its Board of Directors has approved a stock buyback program on Thursday, February 15th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to purchase up to 8.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Alkermes

In other news, SVP Christian Todd Nichols sold 10,417 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $28.10, for a total transaction of $292,717.70. Following the completion of the transaction, the senior vice president now directly owns 65,911 shares of the company’s stock, valued at approximately $1,852,099.10. The sale was disclosed in a filing with the SEC, which is available at this link. 4.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Alkermes during the third quarter worth approximately $387,000. Raymond James & Associates increased its position in shares of Alkermes by 32.4% during the third quarter. Raymond James & Associates now owns 26,592 shares of the company’s stock worth $745,000 after purchasing an additional 6,510 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Alkermes by 4.0% during the third quarter. Bank of New York Mellon Corp now owns 2,761,316 shares of the company’s stock worth $77,344,000 after purchasing an additional 106,749 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Alkermes by 7.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,366 shares of the company’s stock worth $823,000 after purchasing an additional 2,082 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Alkermes by 68.2% during the third quarter. Mackenzie Financial Corp now owns 122,225 shares of the company’s stock worth $3,403,000 after purchasing an additional 49,561 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.